Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioVie Inc. (BIVI)
USD1.77
+0.19 (+12.03%)
US NASDAQ Healthcare Biotechnology
Address
680 West Nye Lane 89703
Carson City, NV, US
Carson City, NV, US
CEO
Cuong Viet Do
Website
bioviepharma.com
IPO
2020-09-18
CIK 1580149 ISIN US09074F5044
Description
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.77
+0.19 (+12.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
124.4K
Beta
0.58
Float Shares
7.50M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | -20.48% | -2.22% | +18.92% | -18.01% | +13.79% | -88.52% | -99.82% | -99.90% | -99.38% | -99.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.77
DCF (Unlevered)
12.82
+624.5%
DCF (Levered)
11.64
+557.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-29.00
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+83.4% ★ Q1'26: +53.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-947.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+227.0% Q1'26: +307.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 |
|---|---|---|---|---|---|
| Revenue |
—
est: -600.0K (+100.0%)
|
—
est: -600.0K (+100.0%)
|
12.80M
12.80M – 12.80M
+2,233.3% YoY
|
367.51M
367.51M – 367.51M
+2,771.2% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-31.95M
|
-16.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-32.18M
|
-17.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-32.12M
est: -149.21M (+78.5%)
|
-17.54M
est: -17.91M (+2.0%)
|
-4.36M
-4.36M – -4.36M
+75.7% YoY
|
639.70M
639.70M – 639.70M
+14,778.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
—
|
8.57M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-73.05
est: -101.00 (+27.7%)
|
-12.12
est: -12.12 (+0.0%)
|
-2.95
-2.95 – -2.95
+75.7% YoY
|
433.00
433.00 – 433.00
+14,778.0% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
172.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Acuitas Group Holdings, LLC | 19.53M | 87.50% | — | 19.53M | — | 11.00 | CO | California | 2021-06-11 | ↗ |
| 2 | Terren S. Peizer | 19.53M | 87.50% | — | 19.53M | — | 19.53M | HC, IN | United States of America | 2021-06-11 | ↗ |
| 3 | LP | 1.26M | 7.60% | — | 1.26M | — | 1.26M | PN | Delaware, United States | 2024-10-25 | ↗ |
| 4 | Maier Joshua Tarlow | 1.26M | 7.60% | — | 1.26M | — | 1.26M | IN | Delaware, United States | 2024-10-25 | ↗ |
| 5 | Management LLC | 1.26M | 7.60% | — | 1.26M | — | 1.26M | OO | Delaware, United States | 2024-10-25 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-26 vs prev Q
New positions
4
Closed positions
30
Increased
4
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DIAMETRIC CAPITAL, LP | 370.0K +— (+0.0%) | 429.2K -273.8K (-38.9%) | 4.67% -2.425 pp | 0.12% -0.146 pp | USD1.90 -38.9% | 2 qtrs — |
| 2 | VANGUARD GROUP INC | 213.5K +84.6K (+65.6%) | 247.7K +2.7K (+1.1%) | 2.70% +0.223 pp | 0.00% +0.000 pp | USD1.61 -28.0% | 2 qtrs — |
| 3 | DRW SECURITIES, LLC | 128.4K +128.4K (+100.0%) | 148.9K +148.9K (+100.0%) | 1.62% +1.621 pp | 0.00% +0.004 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 4 | PRELUDE CAPITAL MANAGEMENT, LLC | 92.1K -52.7K (-36.4%) | 106.8K -168.3K (-61.2%) | 1.16% -1.614 pp | 0.01% -0.014 pp | USD1.90 -38.9% | 2 qtrs — |
| 5 | PHILADELPHIA TRUST CO | 75.0K +— (+0.0%) | 87.0K -56.0K (-39.2%) | 0.95% -0.492 pp | 0.01% -0.004 pp | USD1.90 -38.9% | 2 qtrs — |
| 6 | MORGAN STANLEY | 60.2K +29.9K (+98.8%) | 69.9K +12.3K (+21.4%) | 0.76% +0.179 pp | 0.00% +0.000 pp | USD1.53 -24.2% | 2 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 55.4K +3.0K (+5.7%) | 64.2K -35.3K (-35.4%) | 0.70% -0.305 pp | 0.00% +0.000 pp | USD1.86 -37.6% | 2 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 28.0K -44.9K (-61.6%) | 32.5K -106.0K (-76.5%) | 0.35% -1.045 pp | 0.00% 0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 9 | XTX TOPCO LTD | 21.6K +21.6K (+100.0%) | 25.1K +25.1K (+100.0%) | 0.27% +0.273 pp | 0.00% +0.001 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 10 | TWO SIGMA INVESTMENTS, LP | 21.4K -11.1K (-34.1%) | 24.8K -36.9K (-59.8%) | 0.27% -0.353 pp | 0.00% 0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 11 | CITADEL ADVISORS LLC | 18.2K -86.4K (-82.6%) | 21.1K -177.6K (-89.4%) | 0.23% -1.776 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 12 | FMR LLC | 16.3K +16.3K (+100.0%) | 18.9K +18.9K (+100.0%) | 0.21% +0.206 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 13 | NORTHERN TRUST CORP | 14.2K +14.2K (+100.0%) | 16.5K +16.5K (+100.0%) | 0.18% +0.179 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 14 | SQUAREPOINT OPS LLC | 14.2K -19.1K (-57.4%) | 16.4K -46.8K (-74.0%) | 0.18% -0.460 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 15 | CERITY PARTNERS LLC | 12.4K +12.4K (+100.0%) | 14.4K +14.4K (+100.0%) | 0.16% +0.157 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 16 | JANE STREET GROUP, LLC | 10.5K +10.5K (+100.0%) | 12.2K +12.2K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 17 | ALLWORTH FINANCIAL LP | 2.0K +— (+0.0%) | 2.3K -1.5K (-38.9%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 18 | ROYAL BANK OF CANADA | 2.2K +1.2K (+120.0%) | 2.0K +— (+0.0%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD1.50 -22.7% | 2 qtrs — |
| 19 | CIBC PRIVATE WEALTH GROUP, LLC | 1.1K +— (+0.0%) | 1.3K -811.0 (-38.9%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 20 | PNC FINANCIAL SERVICES GROUP, INC. | 1.0K +— (+0.0%) | 1.2K -740.0 (-38.9%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 21 | UBS GROUP AG | 771.00 -2.1K (-73.6%) | 895.00 -4.7K (-83.9%) | 0.01% -0.046 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 22 | TOWER RESEARCH CAPITAL LLC (TRC) | 617.00 +617.0 (+100.0%) | 716.00 +716.0 (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 23 | SBI SECURITIES CO., LTD. | 236.00 -104.0 (-30.6%) | 274.00 -372.0 (-57.6%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD0.92 +26.1% | 3 qtrs — |
| 24 | BANK OF AMERICA CORP /DE/ | 125.00 +4.0 (+3.3%) | 145.00 -85.0 (-37.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.86 -37.6% | 2 qtrs — |
| 25 | GROUP ONE TRADING, L.P. | 42.00 +— (+0.0%) | 49.00 -31.0 (-38.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.88 -38.3% | 2 qtrs — |
| 26 | WELLS FARGO & COMPANY/MN | 29.00 -15.0 (-34.1%) | 34.00 -50.0 (-59.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.86 -37.6% | 2 qtrs — |
| 27 | NEWEDGE ADVISORS, LLC | 10.00 +— (+0.0%) | 12.00 -7.0 (-36.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 28 | TRADEWINDS CAPITAL MANAGEMENT, LLC | 10.00 +— (+0.0%) | 12.00 -7.0 (-36.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.90 -38.9% | 2 qtrs — |
| 29 | JPMORGAN CHASE & CO | 5.00 +— (+0.0%) | 6.00 -4.0 (-40.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.80 -35.6% | 2 qtrs — |
| 30 | HARBOUR INVESTMENTS, INC. | 3.00 +— (+0.0%) | 3.00 -3.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.67 -30.5% | 2 qtrs — |
| 31 | ALBION FINANCIAL GROUP /UT | 1.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +16.0% | 2 qtrs — |
| 32 | BNP PARIBAS ARBITRAGE, SNC | 2.00 +— (+0.0%) | 2.00 -2.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 -22.7% | 2 qtrs — |
| 33 | DANSKE BANK A/S | 1.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +16.0% | 2 qtrs — |
| 34 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | — -10.0 (-100.0%) | — -19.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 35 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | — -140.0 (-100.0%) | — -266.0 (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 36 | JONES FINANCIAL COMPANIES LLLP | — -1.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 37 | FINANCIAL PERSPECTIVES, INC | — -6.0 (-100.0%) | — -11.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 38 | ADVISOR GROUP HOLDINGS, INC. | — -578.0 (-100.0%) | — -530.0 (-100.0%) | 0.00% -0.011 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 98.4K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
15.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+15,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Sherman Michael Edward | Director | A-Award | A | Stock Option (right to buy) | 341,100 | 1.31 | 446.8K | 341,100 | D | ↗ |
| 2026-01-05 | ROGICH SIGMUND | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.31 | 91.7K | 70,000 | D | ↗ |
| 2026-01-05 | Palumbo Joseph M | Officer | A-Award | A | Stock Option (right to buy) | 132,000 | 1.31 | 172.9K | 132,000 | D | ↗ |
| 2026-01-05 | Lang James Paul | Director | A-Award | A | Stock Option (right to buy) | 330,500 | 1.31 | 433.0K | 330,500 | D | ↗ |
| 2026-01-05 | KIM JOANNE WENDY | Officer | A-Award | A | Stock Option (right to buy) | 110,100 | 1.31 | 144.2K | 110,100 | D | ↗ |
| 2026-01-05 | Farag Kameel D. | Director | A-Award | A | Stock Option (right to buy) | 57,500 | 1.31 | 75.3K | 57,500 | D | ↗ |
| 2026-01-05 | DO CUONG V | Director / Officer | A-Award | A | Stock Option (right to buy) | 665,300 | 1.31 | 871.5K | 665,300 | I | ↗ |
| 2026-01-05 | Chappell Amy Suzon | Director | A-Award | A | Stock Option (right to buy) | 57,500 | 1.31 | 75.3K | 57,500 | D | ↗ |
| 2025-08-07 | DO CUONG V | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.00 | — | 9,992 | I | ↗ |
| 2025-07-17 | Farag Kameel D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-17 | Chappell Amy Suzon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-20 | Sherman Michael Edward | Director | A-Award | A | Stock Option (right to buy) | 23,325 | 1.90 | 44.3K | 23,325 | D | ↗ |
| 2024-12-20 | ROGICH SIGMUND | Director | A-Award | A | Stock Option (right to buy) | 22,070 | 1.90 | 41.9K | 22,070 | D | ↗ |
| 2024-12-20 | Palumbo Joseph M | Officer | A-Award | A | Stock Option (right to buy) | 15,417 | 1.90 | 29.3K | 15,417 | D | ↗ |
| 2024-12-20 | Lang James Paul | Director | A-Award | A | Stock Option (right to buy) | 22,690 | 1.90 | 43.1K | 22,690 | D | ↗ |
| 2024-12-20 | KIM JOANNE WENDY | Officer | A-Award | A | Stock Option (right to buy) | 14,417 | 1.90 | 27.4K | 14,417 | D | ↗ |
| 2024-12-20 | Hariri Robert J | Director | A-Award | A | Stock Option (right to buy) | 21,815 | 1.90 | 41.4K | 21,815 | D | ↗ |
| 2024-12-20 | DO CUONG V | Director / Officer | A-Award | A | Stock Option (right to buy) | 104,502 | 1.90 | 198.6K | 104,502 | I | ↗ |
| 2024-12-20 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 23,155 | 1.90 | 44.0K | 23,155 | D | ↗ |
| 2024-11-20 | Sherman Michael Edward | Director | A-Award | A | Stock Option (right to buy) | 56,900 | 3.36 | 191.2K | 56,900 | D | ↗ |
| 2024-11-20 | ROGICH SIGMUND | Director | A-Award | A | Common Stock | 32,700 | 0.00 | — | 36,926 | D | ↗ |
| 2024-11-20 | Lang James Paul | Director | A-Award | A | Stock Option (right to buy) | 61,600 | 3.36 | 207.0K | 61,600 | D | ↗ |
| 2024-11-20 | Hariri Robert J | Director | A-Award | A | Stock Option (right to buy) | 49,800 | 3.36 | 167.3K | 49,800 | D | ↗ |
| 2024-11-20 | BERMAN RICHARD J | Director | A-Award | A | Common Stock | 34,200 | 0.00 | — | 40,643 | D | ↗ |
| 2024-06-24 | Palumbo Joseph M | Officer | A-Award | A | Stock Option (right to buy) | 156,000 | 0.47 | 73.9K | 156,000 | — | ↗ |
| 2024-06-24 | KIM JOANNE WENDY | Officer | F-InKind | D | Common Stock | 18,250 | 0.47 | 8.7K | 93,940 | — | ↗ |
| 2024-06-24 | DO CUONG V | Director / Officer | A-Award | A | Common Stock | 168,000 | 0.00 | — | 593,948 | — | ↗ |
| 2024-03-04 | DO CUONG V | Director / Officer | P-Purchase | A | Common stock | 10,000 | 1.00 | 10.0K | 435,854 | — | ↗ |
| 2024-02-15 | Palumbo Joseph M | Officer | F-InKind | D | Common Stock | 2,476 | 1.18 | 2.9K | 32,196 | — | ↗ |
| 2024-02-15 | KIM JOANNE WENDY | Officer | F-InKind | D | Common Stock | 2,476 | 1.18 | 2.9K | 39,196 | — | ↗ |
| 2024-02-15 | DO CUONG V | Director / Officer | F-InKind | D | Common Stock | 4,953 | 1.18 | 5.8K | 425,948 | — | ↗ |
| 2023-12-11 | KIM JOANNE WENDY | Officer | A-Award | A | Common Stock | 5,000 | 0.00 | — | 44,148 | — | ↗ |
| 2023-12-01 | GORLIN STEVE | Director | S-Sale | D | Common Stock | 75,680 | 1.69 | 127.9K | 46,358 | — | ↗ |
| 2023-11-30 | DO CUONG V | Director / Officer | P-Purchase | A | Common stock | 10,000 | 1.78 | 17.8K | 68,759 | — | ↗ |
| 2023-11-09 | Sherman Michael Edward | Director | A-Award | A | Stock Option (right to buy) | 89,750 | 3.01 | 270.1K | 89,750 | — | ↗ |
| 2023-11-09 | ROGICH SIGMUND | Director | A-Award | A | Common Stock | 42,254 | 0.00 | — | 42,254 | — | ↗ |
| 2023-11-09 | Lang James Paul | Director | A-Award | A | Stock Option (right to buy) | 93,500 | 3.01 | 281.4K | 93,500 | — | ↗ |
| 2023-11-09 | Hariri Robert J | Director | A-Award | A | Common Stock | 42,254 | 0.00 | — | 42,254 | — | ↗ |
| 2023-11-09 | GORLIN STEVE | Director | A-Award | A | Common Stock | 46,358 | 0.00 | — | 122,038 | — | ↗ |
| 2023-11-09 | BERMAN RICHARD J | Director | A-Award | A | Common Stock | 51,830 | 0.00 | — | 69,235 | — | ↗ |
| 2023-09-05 | GORLIN STEVE | Director | S-Sale | D | Common Stock | 8,560 | 3.05 | 26.1K | 75,680 | — | ↗ |
| 2023-08-22 | BERMAN RICHARD J | Director | S-Sale | D | Common Stock | 10,805 | 3.50 | 37.8K | 16,789 | — | ↗ |
| 2023-06-29 | DO CUONG V | Director / Officer | A-Award | A | Common Stock | 149,500 | 0.00 | — | 425,854 | — | ↗ |
| 2023-06-21 | DO CUONG V | Director / Officer | M-Exempt | D | Restricted stock units | 41,506 | 0.00 | — | 83,014 | — | ↗ |
| 2023-06-07 | Palumbo Joseph M | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 5.78 | 173.4K | 30,000 | — | ↗ |
| 2023-06-07 | KIM JOANNE WENDY | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 5.78 | 115.6K | 20,000 | — | ↗ |
| 2023-06-07 | BERMAN RICHARD J | Director | S-Sale | D | Common Stock | 5,984 | 5.81 | 34.8K | 23,210 | — | ↗ |
| 2023-05-22 | BERMAN RICHARD J | Director | S-Sale | D | Common Stock | 5,000 | 6.50 | 32.5K | 29,194 | — | ↗ |
| 2023-03-28 | BERMAN RICHARD J | Director | S-Sale | D | COMMON STOCK | 5,000 | 8.52 | 42.6K | 36,807 | — | ↗ |
| 2023-03-27 | BERMAN RICHARD J | Director | S-Sale | D | COMMON STOCK | 3,371 | 8.52 | 28.7K | 41,807 | — | ↗ |
| 2023-02-16 | READING CHRISTOPHER | Officer | F-InKind | D | COMMON STOCK | 2,476 | 6.12 | 15.2K | 37,148 | — | ↗ |
| 2023-02-16 | Palumbo Joseph M | Officer | F-InKind | D | Common Stock | 2,476 | 5.51 | 13.6K | 34,672 | — | ↗ |
| 2023-02-16 | MARKHAM PENELOPE | Officer | F-InKind | D | COMMON STOCK | 2,476 | 6.12 | 15.2K | 47,841 | — | ↗ |
| 2023-02-16 | KIM JOANNE WENDY | Officer | F-InKind | D | COMMON STOCK | 2,476 | 6.12 | 15.2K | 39,148 | — | ↗ |
| 2023-02-16 | DO CUONG V | Director / Officer | F-InKind | D | COMMON STOCK | 4,953 | 6.12 | 30.3K | 229,895 | — | ↗ |
| 2023-02-16 | Ahlem Clarence N. | Officer | F-InKind | D | COMMON STOCK | 2,476 | 6.12 | 15.2K | 37,148 | — | ↗ |
| 2022-11-23 | Sherman Michael Edward | Director | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-11-23 | ROGICH SIGMUND | Director | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2022-11-23 | READING CHRISTOPHER | Officer | A-Award | A | COMMON STOCK | 39,624 | 0.00 | — | 39,624 | — | ↗ |
| 2022-11-23 | Palumbo Joseph M | Officer | A-Award | A | COMMON STOCK | 39,624 | 0.00 | — | 39,624 | — | ↗ |
| 2022-11-23 | PEIZER TERREN S | Director | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-11-23 | MARKHAM PENELOPE | Officer | A-Award | A | COMMON STOCK | 39,624 | 0.00 | — | 50,317 | — | ↗ |
| 2022-11-23 | Lang James Paul | Director | A-Award | A | COMMON STOCK | 43,578 | 0.00 | — | 68,622 | — | ↗ |
| 2022-11-23 | KIM JOANNE WENDY | Officer | A-Award | A | COMMON STOCK | 39,624 | 0.00 | — | 41,624 | — | ↗ |
| 2022-11-23 | Hariri Robert J | Director | A-Award | A | COMMON STOCK | 34,240 | 0.00 | — | 34,240 | — | ↗ |
| 2022-11-23 | GORLIN STEVE | Director | A-Award | A | COMMON STOCK | 34,240 | 0.00 | — | 84,240 | — | ↗ |
| 2022-11-23 | DO CUONG V | Officer | A-Award | A | COMMON STOCK | 79,248 | 0.00 | — | 234,848 | — | ↗ |
| 2022-11-23 | BERMAN RICHARD J | Director | A-Award | A | COMMON STOCK | 43,578 | 0.00 | — | 45,178 | — | ↗ |
| 2022-11-23 | Ahlem Clarence N. | Officer | A-Award | A | COMMON STOCK | 39,624 | 0.00 | — | 39,624 | — | ↗ |
| 2022-08-15 | PEIZER TERREN S | Director | A-Award | A | Common Stock | 3,636,364 | 1.65 | 6.00M | 23,166,210 | — | ↗ |
| 2022-06-21 | DO CUONG V | Director / Officer | A-Award | A | Stock Option (right to buy) | 124,520 | 1.69 | 210.4K | 124,520 | — | ↗ |
| 2022-04-05 | Sherman Michael Edward | Director | A-Award | A | Stock Option (Right to buy) | 130,150 | 0.00 | — | 130,150 | — | ↗ |
| 2022-04-05 | ROGICH SIGMUND | Director | A-Award | A | Stock Option (right to buy) | 123,400 | 0.00 | — | 123,400 | — | ↗ |
| 2022-04-05 | Lang James Paul | Director | A-Award | A | Stock Option (right to buy) | 127,900 | 0.00 | — | 127,900 | — | ↗ |
| 2022-04-05 | Hariri Robert J | Director | A-Award | A | Stock Option (right to buy) | 122,250 | 5.04 | 616.1K | 122,250 | — | ↗ |
| 2022-04-05 | GORLIN STEVE | Director | A-Award | A | Stock Option (right to buy) | 122,250 | 0.00 | — | 122,250 | — | ↗ |
| 2022-04-05 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 129,050 | 5.04 | 650.4K | 129,050 | — | ↗ |
| 2022-02-02 | Adams Jonathan M | Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 48,630 | — | ↗ |
| 2022-02-01 | Palumbo Joseph M | Officer | A-Award | A | Stock Option (right to buy) | 124,167 | 3.20 | 397.3K | 124,167 | — | ↗ |
| 2021-12-31 | DO CUONG V | Director / Officer | A-Award | A | Common Stock | 21,710 | 0.00 | — | 58,759 | — | ↗ |
| 2021-12-07 | KIM JOANNE WENDY | Officer | P-Purchase | A | Class A common stock, par value $0.0001 | 2,000 | 5.40 | 10.8K | 2,000 | — | ↗ |
| 2021-11-01 | Palumbo Joseph M | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-20 | READING CHRISTOPHER | Officer | A-Award | A | Stock Option (right to buy) | 124,167 | 7.74 | 961.1K | 124,167 | — | ↗ |
| 2021-08-20 | MARKHAM PENELOPE | Officer | A-Award | D | Stock Option (right to buy) | 124,167 | 7.74 | 961.1K | 124,167 | — | ↗ |
| 2021-08-20 | KIM JOANNE WENDY | Officer | A-Award | D | Stock Option (right to buy) | 124,167 | 7.74 | 961.1K | 124,167 | — | ↗ |
| 2021-08-20 | Do Cuong V | Director / Officer | A-Award | D | Stock Option (right to buy) | 745,000 | 7.74 | 5.77M | 745,000 | — | ↗ |
| 2021-08-20 | Ahlem Clarence N. | Officer | A-Award | A | Stock Option (right to buy) | 124,167 | 7.74 | 961.1K | 124,167 | — | ↗ |
| 2021-08-20 | Adams Jonathan M | Officer | A-Award | D | Stock Option (right to buy) | 124,167 | 7.74 | 961.1K | 124,167 | — | ↗ |
| 2021-07-01 | READING CHRISTOPHER | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-01 | Ahlem Clarence N. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Adams Jonathan M | Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 49,630 | — | ↗ |
| 2021-06-10 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Common Stock | 8,361,308 | 0.00 | — | 19,529,846 | — | ↗ |
| 2020-12-18 | Sherman Michael Edward | Director | A-Award | A | options | 103,100 | 13.91 | 1.43M | 119,906 | — | ↗ |
| 2020-12-18 | ROGICH SIGMUND | Director | A-Award | A | options | 97,300 | 13.91 | 1.35M | 97,300 | — | ↗ |
| 2020-12-18 | Lang James Paul | Director | A-Award | A | options | 99,000 | 13.91 | 1.38M | 120,988 | — | ↗ |
| 2020-12-18 | Hariri Robert J | Director | A-Award | A | Stock Option (right to buy) | 95,900 | 13.91 | 1.33M | 95,900 | — | ↗ |
| 2020-12-18 | GORLIN STEVE | Director | A-Award | A | options | 96,300 | 13.91 | 1.34M | 96,300 | — | ↗ |
| 2020-12-18 | Do Cuong V | Director | A-Award | A | options | 97,500 | 13.91 | 1.36M | 171,366 | — | ↗ |
| 2020-12-18 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 102,500 | 13.91 | 1.43M | 102,500 | — | ↗ |
| 2020-11-03 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 2,430 | 7.95 | 19.3K | 45,100 | — | ↗ |
| 2020-10-30 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 2,570 | 7.97 | 20.5K | 42,670 | — | ↗ |
| 2020-10-21 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 5,000 | 9.19 | 46.0K | 40,100 | — | ↗ |
| 2020-10-15 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 100 | 10.27 | 1.0K | 20,100 | — | ↗ |
| 2020-10-13 | Sherman Michael Edward | Director | A-Award | A | options | 800 | 9.90 | 7.9K | 16,806 | — | ↗ |
| 2020-10-09 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 282 | 9.61 | 2.7K | 20,000 | — | ↗ |
| 2020-10-07 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 4,718 | 9.42 | 44.4K | 19,718 | — | ↗ |
| 2020-10-01 | KIM JOANNE WENDY | Officer | A-Award | A | options | 800 | 9.54 | 7.6K | 2,400 | — | ↗ |
| 2020-09-22 | PEIZER TERREN S | Director / 10% Owner | D-Return | D | 10% Convertible Debenture due 2020 | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-22 | GORLIN STEVE | Director | P-Purchase | A | Class A common stock, par value $0.0001 | 15,000 | 10.00 | 150.0K | 15,000 | — | ↗ |
| 2020-07-13 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Warrants (right to buy) | 299,750 | 0.00 | — | 299,750 | — | ↗ |
| 2020-06-30 | Yeramian Patrick D | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | WIELAND R RICHARD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Sooch Mina | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | ROGICH SIGMUND | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Kumar Hari | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | GORLIN STEVE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Anderson Julie G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-16 | Hariri Robert J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-01-19 | MARKHAM PENELOPE | Officer | A-Award | A | options | 800 | 2.80 | 2.2K | 3,200 | — | ↗ |
| 2020-01-19 | Lang James Paul | Director | A-Award | A | options | 800 | 2.80 | 2.2K | 21,988 | — | ↗ |
| 2020-01-19 | Do Cuong V | Director | A-Award | A | options | 800 | 2.80 | 2.2K | 73,866 | — | ↗ |
| 2020-01-19 | BERMAN RICHARD J | Director | A-Award | A | Stock Option (right to buy) | 800 | 2.80 | 2.2K | 800 | — | ↗ |
| 2020-01-19 | Adams Jonathan M | Officer | A-Award | A | options | 800 | 2.80 | 2.2K | 33,364 | — | ↗ |
| 2020-01-02 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Common Stock | 1,600 | 0.00 | — | 4,258,956 | — | ↗ |
| 2020-01-02 | BERMAN RICHARD J | Director | A-Award | A | Common Stock | 1,600 | 0.00 | — | 1,600 | — | ↗ |
| 2019-10-13 | Sherman Michael Edward | Director | A-Award | A | options | 800 | 7.50 | 6.0K | 16,006 | — | ↗ |
| 2019-10-01 | KIM JOANNE WENDY | Officer | A-Award | A | options | 800 | 8.75 | 7.0K | 1,600 | — | ↗ |
| 2019-09-24 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Common Stock | 1,125,000 | 0.00 | — | 4,252,934 | — | ↗ |
| 2019-06-24 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Common Stock | 1,526,334 | 45.00 | 68.69M | 3,127,934 | — | ↗ |
| 2019-06-24 | BERMAN RICHARD J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-01-19 | Yeramian Patrick D | Officer | — | D | options | 100,000 | 0.03 | 2.5K | 0 | — | ↗ |
| 2019-01-19 | MARKHAM PENELOPE | Officer | — | D | options | 100,000 | 0.03 | 2.5K | 0 | — | ↗ |
| 2019-01-19 | Lang James Paul | Director | A-Award | A | options | 800 | 3.75 | 3.0K | 21,188 | — | ↗ |
| 2019-01-19 | Do Cuong V | Director | A-Award | A | options | 800 | 3.75 | 3.0K | 73,066 | — | ↗ |
| 2019-01-02 | Sooch Mina | Director | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 813,636 | — | ↗ |
| 2019-01-02 | Sherman Michael Edward | Director | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 718,181 | — | ↗ |
| 2019-01-02 | PEIZER TERREN S | Director / 10% Owner | A-Award | A | Common Stock | 1,600 | 0.00 | — | 1,601,600 | — | ↗ |
| 2019-01-02 | Lang James Paul | Director | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 450,000 | — | ↗ |
| 2019-01-02 | Kumar Hari | Director | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 727,272 | — | ↗ |
| 2019-01-02 | Do Cuong V | Director | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 2,871,354 | — | ↗ |
| 2019-01-02 | Adams Jonathan M | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.04 | 7.0K | 6,303,521 | — | ↗ |
| 2018-10-01 | KIM JOANNE WENDY | Officer | — | D | options | 100,000 | 0.07 | 7.0K | 0 | — | ↗ |
| 2018-08-13 | PEIZER TERREN S | Director / 10% Owner | C-Conversion | A | Common Stock | 1,600,000 | 0.00 | — | 1,600,000 | — | ↗ |
| 2018-08-03 | PEIZER TERREN S | Director / 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 1,600,000 | 0.00 | — | 0 | — | ↗ |
| 2018-07-03 | Sherman Michael Edward | Director | A-Award | A | preferred stock | 16,666 | 1.50 | 25.0K | 16,666 | — | ↗ |
| 2018-07-03 | PEIZER TERREN S | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-03 | Lang James Paul | Director | A-Award | A | Preferred Stock | 20,000 | 1.50 | 30.0K | 20,000 | — | ↗ |
| 2018-07-03 | Do Cuong V | Director | A-Award | A | Warrants | 8,666,666 | 0.02 | 156.0K | 9,033,333 | — | ↗ |
| 2018-07-03 | Adams Jonathan M | Director / Officer | A-Award | A | Warrants | 1,000,000 | 0.02 | 18.0K | 4,022,727 | — | ↗ |
| 2018-07-02 | Lang James Paul | Director | A-Award | A | Warrants | 2,000,000 | 0.02 | 36.0K | 2,548,485 | — | ↗ |
| 2018-06-15 | Kumar Hari | Director | A-Award | A | Common Stock | 100,000 | 0.02 | 2.0K | 527,272 | — | ↗ |
| 2018-05-31 | Anderson Julie G | Director | A-Award | A | common stock | 68,500 | 0.02 | 1.1K | 368,500 | — | ↗ |
| 2018-05-15 | Sherman Michael Edward | Director | A-Award | A | common stock | 250,000 | 0.02 | 4.5K | 518,181 | — | ↗ |
| 2018-04-30 | Sooch Mina | Director | A-Award | A | common stock | 150,000 | 0.02 | 3.6K | 613,636 | — | ↗ |
| 2018-03-14 | Anderson Julie G | Director | A-Award | A | options | 100,000 | 0.06 | 6.0K | 200,000 | — | ↗ |
| 2018-01-19 | Yeramian Patrick D | Officer | — | D | options | 100,000 | 0.10 | 10.0K | 0 | — | ↗ |
| 2018-01-19 | MARKHAM PENELOPE | Officer | — | D | options | 100,000 | 0.10 | 10.0K | 0 | — | ↗ |
| 2018-01-19 | Lang James Paul | Director | A-Award | A | options | 100,000 | 0.10 | 10.0K | 548,485 | — | ↗ |
| 2018-01-19 | Do Cuong V | Director | A-Award | A | options | 100,000 | 0.10 | 10.0K | 366,667 | — | ↗ |
| 2018-01-08 | Do Cuong V | Director | A-Award | A | Warrants | 166,667 | 0.15 | 25.0K | 266,667 | — | ↗ |
| 2018-01-02 | Sooch Mina | Director | A-Award | A | common stock | 200,000 | 0.15 | 30.0K | 463,636 | — | ↗ |
| 2018-01-02 | Sherman Michael Edward | Director | A-Award | A | common stock | 200,000 | 0.15 | 30.0K | 268,181 | — | ↗ |
| 2018-01-02 | Lang James Paul | Director | A-Award | A | Warrants | 166,667 | 0.15 | 25.0K | 448,485 | — | ↗ |
| 2018-01-02 | Kumar Hari | Director | A-Award | A | Common Stock | 200,000 | 0.15 | 30.0K | 427,272 | — | ↗ |
| 2018-01-02 | Do Cuong V | Director | A-Award | A | common stock | 200,000 | 0.15 | 30.0K | 2,871,354 | — | ↗ |
| 2018-01-02 | Anderson Julie G | Director | A-Award | A | common stock | 200,000 | 0.15 | 30.0K | 300,000 | — | ↗ |
| 2018-01-02 | Adams Jonathan M | Director / Officer | A-Award | A | common stock | 200,000 | 0.00 | — | 6,103,521 | — | ↗ |
| 2017-11-02 | Sooch Mina | Director | — | D | common stock | 0 | 0.00 | — | 263,636 | — | ↗ |
| 2017-10-30 | Sooch Mina | Director | — | D | Warrants | 56,818 | 0.60 | 34.1K | 0 | — | ↗ |
| 2017-10-27 | Sooch Mina | Director | — | D | options | 100,000 | 0.21 | 21.0K | 0 | — | ↗ |
| 2017-10-25 | WIELAND R RICHARD | Officer | A-Award | A | options | 150,000 | 0.21 | 31.5K | 250,000 | — | ↗ |
| 2017-10-25 | Sherman Michael Edward | Director | — | D | common stock | 0 | 0.00 | — | 68,181 | — | ↗ |
| 2017-10-13 | Sherman Michael Edward | Director | — | D | options | 100,000 | 0.20 | 20.0K | 0 | — | ↗ |
| 2017-09-21 | WIELAND R RICHARD | Officer | — | D | options | 100,000 | 0.20 | 20.0K | 0 | — | ↗ |
| 2017-08-27 | Sherman Michael Edward | Director | — | D | Warrants | 34,091 | 0.60 | 20.5K | 0 | — | ↗ |
| 2017-08-14 | Kumar Hari | Director | A-Award | A | warrants | 45,455 | 0.60 | 27.3K | 213,637 | — | ↗ |
| 2017-07-28 | Lang James Paul | Director | A-Award | A | Warrants | 56,818 | 0.60 | 34.1K | 281,818 | — | ↗ |
| 2017-07-27 | Adams Jonathan M | Director / Officer | A-Award | A | common stock | 45,454 | 0.22 | 10.0K | 5,903,521 | — | ↗ |
| 2017-05-10 | Kumar Hari | Director | — | D | Common Stock | 0 | 0.00 | — | 136,364 | — | ↗ |
| 2017-05-02 | Kumar Hari | Director | — | D | options | 100,000 | 0.23 | 23.0K | 0 | — | ↗ |
| 2017-03-15 | Anderson Julie G | Director | A-Award | A | Warrants | 50,000 | 0.50 | 25.0K | 50,000 | — | ↗ |
| 2017-03-14 | Anderson Julie G | Director | — | D | options | 100,000 | 0.22 | 22.0K | 0 | — | ↗ |
| 2016-12-08 | Lang James Paul | Director | A-Award | A | options | 100,000 | 0.21 | 21.0K | 225,000 | — | ↗ |
| 2016-12-08 | Do Cuong V | Director | A-Award | A | options | 100,000 | 0.21 | 21.0K | 100,000 | — | ↗ |
| 2016-12-07 | Lang James Paul | Director | — | D | common stock | 0 | 0.00 | — | 250,000 | — | ↗ |
| 2016-11-16 | Yeramian Patrick D | Officer | — | D | options | 100,000 | 0.25 | 25.0K | 0 | — | ↗ |
| 2016-11-16 | MARKHAM PENELOPE | Officer | — | D | options | 100,000 | 0.25 | 25.0K | 0 | — | ↗ |
| 2016-11-11 | Lang James Paul | Director | — | D | Warrants | 125,000 | 0.50 | 62.5K | 0 | — | ↗ |
| 2016-04-11 | Do Cuong V | Director | — | I | common stock | 0 | 0.00 | — | 2,671,354 | — | ↗ |
| 2016-04-11 | Adams Jonathan M | Director / Officer | — | D | options | 3,000,000 | 0.06 | 180.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
7.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Cuong Do Chief Executive Officer and President | 618.0K | 92.7K | — | 149.4K | — | — | 860.1K | 17.37% | ↗ |
| 2 | 2025 | Joseph Palumbo Chief Medical Officer | 560.0K | 84.0K | — | 22.1K | — | — | 666.1K | 3.31% | ↗ |
| 3 | 2025 | Joanne Wendy Kim Chief Financial Officer and Corporate Secretary | 295.0K | 105.0K | — | 20.6K | — | — | 420.6K | 4.90% | ↗ |
| 4 | 2024 | Cuong Do Chief Executive Officer and President | 618.0K | — | 79.6K | 79.5K | — | — | 777.1K | 20.47% | ↗ |
| 5 | 2024 | Joseph Palumbo Chief Medical officer | 560.0K | — | 55.0K | 54.6K | — | — | 669.6K | 16.37% | ↗ |
| 6 | 2024 | Joseph Palumbo Chief Medical Officer | 560.0K | — | 55.0K | 54.6K | — | — | 669.6K | 16.37% | ↗ |
| 7 | 2024 | Joanne Wendy Kim Chief Financial Officer, Treasurer and Corporate Secretary | 270.0K | — | 34.6K | 34.7K | — | — | 339.3K | 20.41% | ↗ |
| 8 | 2024 | Joanne Wendy Kim Chief Financial Officer and Corporate Secretary | 270.0K | — | 34.6K | 34.7K | — | — | 339.3K | 20.41% | ↗ |
| 9 | 2023 | Cuong Do Chief Executive Officer and President | 618.0K | 463.5K | 734.7K | 521.5K | — | — | 2.34M | 53.74% | ↗ |
| 10 | 2023 | Joseph Palumbo Chief Medical officer | 525.0K | 197.0K | 242.5K | 126.0K | — | — | 1.09M | 33.79% | ↗ |
| 11 | 2023 | Joanne Wendy Kim Chief Financial Officer, Treasurer and Corporate Secretary | 246.8K | 150.6K | 242.5K | 84.0K | — | — | 723.9K | 45.10% | ↗ |
| 12 | 2022 | Cuong Do Chief Executive Officer and President | 300.0K | 400.0K | 210.4K | 3.63M | — | — | 4.54M | 84.59% | ↗ |
| 13 | 2022 | Joseph Palumbo Chief Medical officer | 525.0K | 197.0K | 242.5K | 126.0K | — | — | 1.09M | 33.79% | ↗ |
| 14 | 2022 | Joanne Wendy Kim Chief Financial Officer, Treasurer and Corporate Secretary | 235.0K | 127.7K | — | 582.3K | — | — | 945.0K | 61.62% | ↗ |
| 15 | 2022 | Joseph Palumbo Chief Medical officer Former President and Chief Operating Officer | 333.3K | 239.2K | — | 244.5K | — | — | 817.0K | 29.92% | ↗ |
| 16 | 2021 | Cuong Do Chief Executive Officer and President | — | — | 454.8K | — | — | — | 454.8K | 100.00% | ↗ |
| 17 | 2021 | Cuong Do President and Chief Executive Officer | — | — | — | 409.3K | — | — | 409.3K | 100.00% | ↗ |
| 18 | 2021 | Jonathan Adams Former President and Chief Operating Officer | — | — | — | 20.7K | — | 17.2K | 287.9K | 7.20% | ↗ |
| 19 | 2021 | Joseph Palumbo Chief Medical officer Former President and Chief Operating Officer | 250.0K | — | — | 20.7K | — | — | 270.7K | 7.65% | ↗ |
| 20 | 2021 | Joanne Wendy Kim Chief Financial Officer, Treasurer and Corporate Secretary | 120.6K | — | — | 4.7K | — | — | 125.3K | 3.75% | ↗ |
| 21 | 2021 | Joanne Wendy Kim Chief Financial Officer and Corporate Secretary | — | — | — | 4.7K | — | — | 125.3K | 3.75% | ↗ |
| 22 | 2020 | Jonathan Adams Former President and Chief Operating Officer | — | — | — | 7.0K | — | — | 257.0K | 2.71% | ↗ |
| 23 | 2020 | Joanne Wendy Kim Chief Financial Officer and Corporate Secretary | — | — | — | 4.1K | — | — | 116.6K | 3.51% | ↗ |
| 24 | 2020 | Terren S. Peizer Chairman of the Board and Former Chief Executive Officer | — | — | — | 5.6K | — | — | 5.6K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cuong Viet Do | President, Chief Executive Officer & Director | 710.7K | male |
| Joseph Palumbo | Executive Vice President of R&D and Chief Medical Officer | 644.0K | — |
| Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary | 400.0K | female |
| Denise Smith | Senior Vice President of Manufacturing & Development | — | female |
| Christopher L. Reading | Senior Vice President of Alzheimer's Disease Program | — | — |
| Penelope Markham | Senior Vice President of Liver Disease Program | — | — |
| Clarence N. Ahlem | Senior Vice President of Operations | — | male |
| David Morse | Senior Vice President & Chief Regulatory Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIVI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
